Over the past six months, our team has achieved several milestones:
1. REB Approval: We successfully received Research and Ethics Board (REB) approval for our study titled "An Integrative Naturopathic Treatment Model: A Chart Review of Survival Outcomes" from the Canadian College of Naturopathic Medicine. This is the first and critical step in order to conduct human research.
2. Grant Application: We successfully applied for and were awarded a highly competitive $5,000 grant from the Oncology Association of Naturopathic Physicians (OncANP) for our study. This grant not only provides crucial financial support but also validates the significance and potential impact of our research within the integrative oncology community.
3. Oral Presentation at SIO® 21st International Conference:
The Society for Integrative Oncology (SIO) International Conference is a premier event in the field of integrative oncology, attracting leading researchers, practitioners, and healthcare professionals from around the world. It serves as a crucial platform for sharing cutting-edge research, innovative treatment modalities, and best practices in the integration of conventional and complementary therapies in cancer care.
We are thrilled to announce that our paper titled "Integrative Naturopathic Treatment Model for Colorectal Cancer: A Retrospective Study" has been accepted for an oral presentation at the SIO 21st International Conference. The conference will be held at the City of Hope Hospital in Costa Mesa, CA, USA, from October 25 to October 27, 2024. This recognition underscores the significance of our work and its contribution to the advancement of integrative oncology.
4. Data Analysis: We have been analyzing data from stage 4 colorectal cancer survivors and glioblastoma multiforme (GBM) survivors.
Our analysis involved comparing the colorectal cancer and GBM data with controls sampled from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, a de-identified, publicly available database of cancer cases in the United States.
To ensure robust data analysis in our study, we implemented advanced statistical methodologies. We used a technique called propensity score matching to select control patients from a large cancer database, ensuring they were similar to our treatment group in keyways like age, sex, and treatment history. This method helps balance the groups and reduce biases. We also carefully handled the timing of treatments to avoid immortal time bias (e.g., survival bias), which can skew results. We then compared survival rates using established statistical methods to determine if our treatment had a significant impact. Our approach aims to provide reliable and unbiased results, demonstrating the effectiveness of our integrative naturopathic treatment model.
5. Manuscript Preparation: We have started drafting the introduction and methods sections of our CRC paper and plan to publish in the Integrative Cancer Therapies journal, or another high impact peer-reviewed PubMed-indexed journal.
Our study revealed promising results for the effectiveness of integrative oncology treatments. We compared two groups of cancer patients: those receiving standard treatments and those receiving integrative oncology care. For the entire group, the median survival time was 18 months for the standard treatment group and 29 months for the integrative oncology group, though this difference was not statistically significant.
However, when focusing on patients who began integrative oncology treatment within 90 days of diagnosis, we saw more significant results. This subgroup had a 55% lower risk of death compared to the standard treatment group, indicating that early integrative care can significantly improve survival rates. These findings suggest that integrative oncology, especially when started early, may offer substantial benefits in extending the lives of cancer patients.
To further validate our results and interpretations, we are conducting an analysis to compare the subgroup of patients who began integrative oncology treatment within 90 days of diagnosis to those who started their treatment more than 90 days after their diagnosis.
These efforts represent significant progress in our research endeavors, and we are excited about the potential impact of our findings.
Prepared by Sara Izadi, PhD
Research Associate, Integrated Health Clinic, Research Department
Postdoctoral Fellow, BC Cancer